Sana Biotechnology, Inc.
- SANA
- NASDAQ
- Biotechnology
- Cell Engineering
- Cell Therapy (Oncology/Diabetes)
$2.37
Today +2.83%Quote Oct 20, 2026, 02:54 PM UTC
−25.81%over the last month
Max drawdown −31.8%From 1-month high −30.9%3 months −27.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Sana Biotechnology
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
142
Founded
2018
Market value
$708.0M
Quote Oct 20
Floor
$2.11
10.8% below price
Resistance
$2.43
2.7% above price
Price vs analyst targets
11 analysts
Lowest target
$7.00Highest target
$12.00
$7.00Highest target
$12.00
- Price $2.37
- Average target $8.50
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 259% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about SANAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free